All In Biotech

Drug Trial Radar · NCT07524101

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

Utilizing Lipid-lowering Therapy With Moderate-intensity Statin Plus Ezetimibe in Chronic Kidney Disease Patients With Concomitant Atherosclerotic Cardiovascular Disease: ULTRA-CKD Trial

Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,952 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,952

Planned (sponsor's estimate)

Start

May 28, 2026

Primary completion

Jan 22, 2031

Study completion Jan 22, 2031

Sponsor

Lead sponsor
Yonsei UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with chronic kidney disease (CKD) and concomitant atherosclerotic cardiovascular disease (ASCVD). Patients with CKD are at very high risk for ASCVD. In this population, it is important to establish a lipid-lowering strategy that optimizes cardiovascular outcomes while ensuring long-term safety. While high-intensity statins are generally considered as initial treatment option for secondary prevention, the optimal strategy for CKD patients remains to be clinicaly defined. This study aims to evaluate whether the combination of moderate-intensity statin and ezetimibe is non-inferior to high-intensity statin monotherapy in terms of 3-year composite of major adverse cardiovascular events.

Conditions

  • Renal Insufficiency
  • Atherosclerosis
  • Dyslipidemia
  • Hypercholesterolemia
  • Cardiovascular Diseases

Interventions

  • Moderate-intensity statin and ezetimibe combination therapyDrug

    Participants will receive moderate-intensity statin plus ezetimibe (pitavastatin 1-4 mg + ezetimibe 10 mg once daily or atorvastatin 10-20 mg + ezetimibe 10 mg once daily), with 36-month follow-up.

  • High-intensity statin monotherapyDrug

    Participants will receive high-intensity statin monotherapy (atorvastatin 40 mg once daily), with 36-month follow-up.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major adverse cardiovascular eventsTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.